High level of primary drug resistance in Mali

HIV Medicine

Volumn 11, Issue 6, 2010, Pages 404-411

  Haidara, A ^a   Chamberland, A ^a,b   Sylla, M ^b   Aboubacrine, S A ^c   Cisse M ^d   Traore, H A ^c   Maiga, M Y ^e   Tounkara, A ^c   Nguyen, V K ^a   Tremblay, C ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Hopital National du Point G   (Mali)

^d CESAC   (Mali)

^e HÔPITAL GABRIEL TOURÉ   (Mali)

Author keywords

HIV subtypes; Mutations; Primary resistance

Indexed keywords

ALANINE; ANTIRETROVIRUS AGENT; ARGININE; ASPARAGINE; ASPARTIC ACID; GLUTAMIC ACID; GLYCINE; ISOLEUCINE; LEUCINE; LYSINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PHENYLALANINE; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THREONINE; TYROSINE; VALINE;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BACTERIAL STRAIN; CARBOXY TERMINAL SEQUENCE; CODON; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MALI; MUTATIONAL ANALYSIS; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MALI; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PREVALENCE; PROSPECTIVE STUDIES; RNA, VIRAL; YOUNG ADULT;

EID: 77954599757     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00806.x     Document Type: Article

References (42)

1. Laurent CC, Kouanfack S, Koulla-Shiro N. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1 infected adults in Cameroon: open-label multicentre trial. Lancet 2004, 364:29-34.
2. Lange JM, Perriens J, Kuritzkes D. What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection. AIDS 2004, 18(Suppl 3):S69-S74.
3. Montes B, Vergne L, Peeters M. Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J Acquir Immune Defic Syndr 2004, 35:329-336.
4. Deshpande A, Recordon-Pinson P, Deshmukh R. Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India, and detection of rare resistance mutations. AIDS Res Hum Retroviruses 2004, 20:1032-1035.
5. Turriziani O, Russo G, Lichtner M. Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon. AIDS Res Hum Retroviruses 2008, 24:781-785.
6. Politique et protocoles de prise en charge antirétrovirale du VIH/SIDA. Janvier 2006 Ministère de la Santé du Mali, Secrétariat Général et Comité Sectoriel de Lutte contre le SIDA
7. Derache A, Maiga AI, Traore O. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J Antimicrob Chemother 2008, 62:456-463.
8. Thompson SD, Higgins DG, Gibson TJ, Clustal W. Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994, 22:4673-4680.
9. Derache A, Traore O, Koita V. Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali. Antivir Ther 2007, 12:123-129.
10. Ariyoshi K, Matsuda M, Miura H. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr 2003, 33:336-342.
11. Kinomoto M, Appiah-Opong R, Brandful JA. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin Infect Dis 2005, 41:243-251.
12. Quan Y, Brenner BG, Marlink RG. Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Res Hum Retroviruses 2003, 19:743-753.
13. Brenner B, Turner D, Oliveira M. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003, 17:F1-F5.
14. Grossman Z, Paxinos EE, Averbuch D. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother 2004, 48:2159-2165.
15. Sylla M, Chamberland A, Boileau C. Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. Antivir Ther 2008, 13:141-148.
16. http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf, WHO., Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. 2003 revision. Geneva: World Health Organization, 2003. Available at, (accessed 7 June 2004)
17. Grant RM, Hecht FM, Warmerdam M. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002, 288:181-188.
18. Vergne LM, Peeters E, Mpoudi-Ngole A. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000, 38:3919-3925.
19. Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 2007, 59:1047-1056.
20. Nyombi BM, Holm-Hansen C, Kristiansen KI. Prevalence of reverse transcriptase and protease mutations associated with antiretroviral drug resistance among drug-naïve HIV-1 infected pregnant women in Kagera and Kilimanjaro regions, Tanzania. AIDS Res Ther 2008, 21:13.
21. Agwale SM, Zeh C, Paxinos E. Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients. AIDS Res Hum Retroviruses 2006, 22:22-26.
22. Pillay V, Ledwaba J, Hunt G. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008, 13:101-107.
23. Vidal N, Mulanga C, Bazepeo SE. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). AIDS Res Hum Retroviruses 2006, 22:202-206.
24. Toni TD, Recordon-Pinson P, Minga A. Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Côte d'Ivoire: ANRS 1257 study. AIDS Res Hum Retroviruses 2003, 19:713-717.
25. Bonfim I, Sousa B, Lima A. Resistance to antiretroviral in drug-naive HIV-1 infected patients in São Tome e Príncipe. In: 4th European HIV Drug Resistance Workshop, Abstract 26 (2006) Monte Carlo
26. Chaix MLD, Descamps M, Harzic V. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS 2003, 17:2635-2643.
27. Perno CF, Cozzi-Lepri A, Balotta CF. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with PI-based therapy. J Infect Dis 2001, 184:983-991.
28. Marcelin AG, Flandre P, de Mendoza C. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients. Antivir Ther 2007, 12:247-252.
29. Marcelin AG, Flandre P, Molina JM. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials. Antimicrob Agents Chemother 2008, 52:4251-4257.
30. Grant PEC, Wong R, Rode R. Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores. Antimicrob Agents Chemother 2008, 52:4050-4056.
31. Para MF, Glidden DV, Coombs RW. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333. J Infect Dis 2000, 182:733-743.
32. Vora S, Marcelin AG, Günthard HF. Swiss HIV cohort study: clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS 2006, 2:35-40.
33. Baxter JD, Schapiro JM, Boucher CA. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006, 80:10794-10801.
34. Nadembega WM, Giannella S, Simpore J. Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso. J Med Virol 2006, 78:1385-1391.
35. King MSR, Rode I, Cohen-Codar V. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2007, 51:3067-3074.
36. Rhee SYJ, Taylor G, Wadhera A. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci USA 2006, 103:17355-17360.
37. Zolopa AW, Towner D, Butcher S. Resistance profile after viral rebound on atazanavir-containing therapy: focus on protease inhibitor-naive subjects in the IMPACT study (BMS AI424-128). HIVDRW2007
38. Delaugerre CD, Mathez G, Peytavin H. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients. AIDS 2007, 21:1210-1213.
39. Brehm JH, Koontz D, Meteer JD. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. J Virol 2007, 81:7852-7859.
40. Nikolenko GN, Delviks-Frankenberry KA, Palmer S. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. Proc Natl Acad Sci USA 2007, 2:317-322.
41. Johnson VA, Brun-Vezinet F, Clotet B. Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med 2008, 16:62-68.
42. Zelina S, Sheen CW, Radzio J, Mellors JW, Sluis-Cremer N. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrob Agents Chemother 2008, 52:157-163.